A pilot study of levetiracetam as a sensitizer of temozolomide for newly diagnosed glioblastoma: A prospective, open-label, phase II study (KBTS-1601 study).
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chae-Yong | - |
dc.contributor.author | Hwang, Kihwan | - |
dc.contributor.author | Chang, Jong Hee | - |
dc.contributor.author | Kang, Seok-Gu | - |
dc.contributor.author | Jung, Tae-Young | - |
dc.contributor.author | Kim, Jeong Hoon | - |
dc.contributor.author | Kim, Se-Hyuk | - |
dc.contributor.author | Kang, Shin-Hyuk | - |
dc.contributor.author | Hong, Yong-Kil | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Choi, Byung Se | - |
dc.contributor.author | Kim, YuJung | - |
dc.contributor.author | Choe, Ghee Young | - |
dc.date.accessioned | 2024-02-08T02:00:16Z | - |
dc.date.available | 2024-02-08T02:00:16Z | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.issn | 1527-7755 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/71840 | - |
dc.description.abstract | Background: We evaluated the survival benefit of levetiracetam as a chemosensitizer of temozolomide for patients with newly diagnosed glioblastoma. Methods: This was an open-label, multicenter, phase II study (NCT02815410). Eligible patients were aged 18 years or older and had newly diagnosed glioblastoma with an ECOG performance status of 0-2. All patients received radiotherapy with concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200 mg/m2/day for 5 days during six 28-day cycles). The first dose of levetiracetam was given just after the surgery at 250mg orally twice a day and increased up to 500mg twice a day prior to radiation. This prospective study was designed to test whether levetiracetam in conjunction with temozolomide improved survival. The historical control group was based on data from a study by Gwak et al. for Korean patients with newly diagnosed glioblastoma with a median overall survival(OS) of 17.5 months and a median progression-free survival (PFS) of 10.1 months. Results: Forty-six patients were enrolled between August 2016 and January 2019. The median follow-up duration was 24.9 months (range, 7.9-35.5). All patients completed standard radiation therapy with temozolomide, and 39 (84.8%) patients completed six cycles of adjuvant temozolomide. Median overall survival (OS) was 30.0 months, and median PFS was 15.0 months. OS at 6, 12, and 24 months was 100%, 91.3%, and 60.7%, respectively. PFS at 6, 12, and 24 months was 93.2%, 65.3%, and 22.6%, respectively. Conclusions: Addition of levetiracetam during concurrent and adjuvant temozolomide along with radiotherapy in patients with newly diagnosed glioblastoma may result in improved outcomes compared to historical data and merits further study. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | A pilot study of levetiracetam as a sensitizer of temozolomide for newly diagnosed glioblastoma: A prospective, open-label, phase II study (KBTS-1601 study). | - |
dc.type | Article | - |
dc.identifier.doi | 10.1200/JCO.2020.38.15_suppl.2560 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.38, no.15 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000560368301255 | - |
dc.citation.number | 15 | - |
dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 38 | - |
dc.type.docType | Meeting Abstract | - |
dc.publisher.location | 미국 | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.